Преднизолон

Quick links to important sections

Преднизолон

Selected form

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Преднизолон

Prednisolone is a widely prescribed, powerful medication belonging to the glucocorticoid class of corticosteroids. It is used to manage numerous inflammatory, autoimmune, and allergic conditions.

Property Description
Active ingredient Prednisolone
Form Oral tablet, liquid solution
Pharmacological class Corticosteroid (Glucocorticoid)
Common use Reducing severe inflammation and immune response
Origin Synthetic (Man-made version of cortisol)

Core Definition and Therapeutic Role

Prednisolone is a prescription-only medication that functions as a synthetic derivative of the naturally occurring hormone, cortisol, which is produced by the adrenal glands. It is the International Non-proprietary Name (INN) for this compound.

As a glucocorticoid, it acts primarily as a potent anti-inflammatory and immunosuppressive agent. It achieves its therapeutic effect by decreasing inflammation, which in turn helps relieve symptoms like pain, swelling, and allergic reactions. Its ability to control inflammation is clinically recognized across decades of medical practice.

Prednisolone is a cornerstone therapy for rapidly controlling acute episodes, such as severe asthma flares or allergic reactions, where a quick reduction in the immune response is essential. Furthermore, prednisolone can be used as a replacement therapy in individuals whose bodies do not produce enough natural steroids (adrenal insufficiency).

Regulatory References

  1. Prednisolone: MedlinePlus Drug Information
  2. Prednisolone tablet - DailyMed - NIH

What side effects are possible with Преднизолон?

Possible Side Effects and Safety Information

Prednisolone, a glucocorticoid, can cause a wide spectrum of adverse reactions, with the dose and duration of therapy being the primary determining factors for their severity and frequency. The safety profile is structured by System Organ Class (SOC) based on regulatory standards.

Key Safety Information and Serious Adverse Reactions

Prolonged or high-dose use of prednisolone is associated with serious, clinically significant risks, including suppression of the hypothalamic-pituitary-adrenal (HPA) axis, which requires gradual withdrawal of the drug to prevent acute adrenal insufficiency. Other major risks documented in regulatory sources include:

  • Infections: Increased susceptibility to new infections, and the potential for exacerbation or reactivation of latent infections. Signs of infection may be masked.
  • Metabolic and Endocrine: Development of cushingoid features (e.g., 'moon face,' 'buffalo hump'), hyperglycemia (leading to or worsening diabetes), and growth retardation in children.
  • Musculoskeletal: Osteoporosis, pathologic fractures, and aseptic necrosis of bone (especially the femoral head).
  • Psychiatric: Behavioral and mood disturbances, including euphoria, severe depression, and psychosis.
  • Ocular: Cataracts, glaucoma, and exophthalmos.
  • Gastrointestinal: Peptic ulceration with possible perforation and hemorrhage.

Population-Specific Considerations and Restrictions

Therapy should be used with particular caution in patients with pre-existing conditions such as heart failure, uncontrolled hypertension, diabetes mellitus, active or latent infection, and peptic ulcer disease. Prednisolone is generally contraindicated in patients with systemic fungal infections and ocular herpes simplex. For children, the lowest effective dose must be used for the shortest possible duration to monitor and mitigate the risk of growth suppression. For all patients, the lowest effective dose for the minimum required duration is essential to minimize the risk of disabling side effects.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information indicates that acute overdosage with Prednisolone is generally assessed as unlikely to result in a life-threatening situation (FDA statement). The clinical presentation of overdosage is primarily defined by the exacerbation of known systemic adverse reactions associated with glucocorticoid exposure.

Documented Overdose Presentations

System Affected Manifestations Reported (Exacerbated Effects)
Cardiovascular/Fluid Hypertension, fluid retention, and signs of hypokalemia
Neurological Convulsions (seizures), psychotic manifestations, and severe depression
Chronic Exposure Manifestations consistent with Cushing’s syndrome

Immediate Actions and Management

Individuals must seek immediate emergency medical attention or contact a certified Poison Help Center for suspected overdosage. Urgent medical help is explicitly required, according to regulatory guidance, if the person has collapsed, is having a seizure, is experiencing trouble breathing, or cannot be awakened (NIH guidance).

Since no specific antidote is known for acute toxicity, the required treatment is symptomatic and supportive. This approach includes monitoring of vital signs and electrolyte balance to correct any metabolic disturbances, such as hypokalemia. An enhanced pharmacological effect may be observed in patients with pre-existing conditions like hypothyroidism or cirrhosis.

Therapeutic Uses of Преднизолон

Prednisolone is commonly used across a broad spectrum of conditions characterized by periods of heightened symptoms, primarily used in situations involving certain distressing symptoms across domains where additional symptomatic support is needed.

The medication is applied to manage symptoms in conditions like severe arthritis, systemic lupus, and inflammatory bowel disease, as well as for supportive symptom management in acute allergic and respiratory events, and as essential hormone replacement for adrenal insufficiency. It is applied to help support functional stability and offers symptomatic relief that helps patients cope more steadily with difficult episodes. The medication is often used during phases when symptoms become more noticeable and short-term symptomatic assistance is needed.


Quick Fact: Relief for Inflammation and Systemic Imbalance

  • Primary Benefit: Contributes to easing the overall symptom load and helps address groups of symptoms that may become intense or disruptive.
  • Key Contexts: Used in clinical settings involving acute or unstable symptom patterns, and as maintenance therapy for conditions of systemic imbalance.
  • Symptom Focus: Addresses clusters that may become intense or disruptive, contributing to improved day-to-day comfort during symptomatic periods.

Regulatory References

  1. FDA DailyMed Label for Prednisolone Oral Solution

Eligibility and Restrictions for Use

Regulatory documents define population eligibility for Prednisolone through a framework of absolute prohibitions and specific restrictions.

Eligibility Scope

Classification Population or Condition Status
Contraindicated Patients with Systemic Fungal Infections Must NOT be used (unless concurrent anti-infective therapy is provided).
Contraindicated Known Hypersensitivity to prednisolone or any component Must NOT be used.
Contraindicated Receiving Live or Live-Attenuated Vaccines Must NOT be used at immunosuppressive doses.

Specific Population and Condition Restrictions

Category Regulatory Statement (Use With Caution)
Age-Related Children: Use requires close monitoring for growth retardation, which may be irreversible. Older Adults: Use requires caution due to increased risk of complications like osteoporosis and hypertension.
Organ Function Patients with Severe Hepatic Impairment or Renal Insufficiency Use requires caution and careful monitoring.
Comorbidity Pre-existing conditions like diabetes mellitus, active or latent peptic ulcer, hypertension, congestive heart failure, or osteoporosis Use requires caution and specialized risk management.
Reproductive Pregnancy/Lactation: Conditional Use. Recommended only if the potential benefit outweighs the documented risks (e.g., potential fetal harm with first-trimester use).

Connection to the overall eligibility profile: Regulatory authorities establish that the general adult and pediatric populations are eligible for use, provided they are free from absolute contraindications. The profile is primarily defined by the requirement for special caution and monitoring in populations with pre-existing organ limitations, metabolic disorders, and specific infectious vulnerabilities.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The activity of Prednisolone can be altered by other medications that affect its metabolism in the body, primarily through the CYP3A4 enzyme system.

Interacting Product Category Potential Effect & Clinical Note
CYP3A4 Inducers (e.g., Rifampin, Phenytoin) May decrease Prednisolone plasma concentrations, potentially reducing its effectiveness. Higher corticosteroid doses may be required.
CYP3A4 Inhibitors (e.g., Ketoconazole, Macrolides) May increase Prednisolone plasma concentrations, raising the risk of corticosteroid-related adverse effects. Lower corticosteroid doses may be required.
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) (including Aspirin) Concurrent use significantly increases the risk of gastrointestinal side effects, such as ulcers and bleeding.
Antidiabetic Agents (e.g., Insulin, Glipizide) Prednisolone can increase blood glucose levels. Dosage adjustments of antidiabetic drugs may be necessary to maintain glucose control.
Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) Increases the risk of hypokalemia (low potassium). Patients require close monitoring of serum electrolyte levels.
Oral Anticoagulants (e.g., Warfarin) Co-administration can lead to an inconsistent anticoagulant response. Frequent monitoring of coagulation indices (e.g., INR) is essential.
Fluoroquinolones (e.g., Ciprofloxacin) May increase the risk of tendon rupture, especially in elderly patients.
Live or Live-Attenuated Vaccines Should not be administered when receiving immunosuppressive doses, as the corticosteroid may diminish the immune response.

Combinations with specific drugs such as Mifepristone are generally not recommended due to potential counteraction of hormonal effects.

Mechanism of Action

Prednisolone's mechanism of action is governed by its role as an agonist of the intracellular Glucocorticoid Receptor (GR), a protein found in nearly all nucleated cells. The drug-receptor complex translocates into the cell nucleus, where it acts as a modulator of gene expression.

This genomic action proceeds through two major pathways: Transrepression and Transactivation. Transrepression is the dominant anti-inflammatory component, achieved by physically blocking pro-inflammatory transcription factors, notably NF-kappa B. This significantly reduces the synthesis of signaling molecules like cytokines and chemokines. Simultaneously, Transactivation up-regulates the production of anti-inflammatory proteins, such as Annexin-1. Annexin-1 then indirectly inhibits the enzyme Phospholipase A2 ( PLA2), thereby suppressing the entire Arachidonic Acid Cascade and blocking the formation of inflammatory mediators like prostaglandins. This widespread reduction in mediator synthesis and immune cell activity generates systemic anti-inflammatory and immunosuppressive physiological effects. Due to its reliance on gene transcription (genomic action), the maximal physiological consequence is intrinsically delayed. Furthermore, this GR agonism initiates a negative feedback loop that suppresses the body's natural cortisol production (HPA axis).

Dosage and Administration Information

The use of prednisolone is primarily systemic, administered via the oral route as a tablet, solution, or orally disintegrating tablet. The required dosage is highly individualized based on the specific condition being treated, but typical initial adult doses range from 5 mg to 60 mg per day.

Administration Schedule and Timing

The medication is generally administered as a single dose once a day, commonly taken in the morning with food or milk to help mitigate gastrointestinal irritation. Taking the dose in the morning aligns with the body's natural circadian rhythm for cortisol production. In long-term maintenance protocols, alternate-day therapy may be prescribed.

Dosing and Procedural Rules

Dosage for pediatric patients is determined based on body weight or body surface area (BSA) and requires careful calculation. For liquid solutions, a calibrated measuring device must be used to ensure accurate administration. Dosage forms like delayed-release tablets must be swallowed whole and should not be crushed, broken, or chewed. Dose reduction may also be necessary in patients with hypoalbuminaemia.

Duration and Discontinuation

Following prolonged therapy, the medication must never be discontinued abruptly. Instead, the dose must be gradually reduced (tapered) over time to allow the body's natural adrenal function to recover. If a dose is missed, it should be skipped if it is almost time for the next dose; doubling the dose is not permitted.

Recent Clinical Evidence

Research evidence / Overview of studies for Преднизолон

Evidence for Use in Managing Inflammatory Autoimmune Conditions (e.g., RA, Lupus, IBD)

Prednisolone was studied for conditions involving inflammation, functional imbalance, and fluctuating or episodic manifestations. For conditions like Rheumatoid Arthritis (RA), research has explored the effects of the medicine through Randomized Controlled Trials (RCTs) and long-term observational studies. These studies examined outcomes related to physical discomfort and functional capacity, such as how patients reported their pain and ability to perform daily activities.

For Inflammatory Bowel Disease (IBD), including Crohn’s disease and Ulcerative Colitis, research examined short-term outcomes related to the induction of remission. RCTs and systematic reviews were evaluated in populations experiencing periods of heightened symptom activity. Uncertainty remains regarding the evidence for very low maintenance doses (below 5 mg per day), as the effects in some subgroups are less uniformly established. There is limited information for long-term outcomes when using the systemic form for treatment, as the systemic form is typically used short-term.


Evidence for Use in Acute Flares and Respiratory Exacerbations

Prednisolone was studied for short-term use in conditions associated with acute or disruptive episodes, such as asthma exacerbations. Research in this area is characterized by very short-term RCTs and systematic reviews. Studies examined outcomes related to episodic or acute changes, such as the time elapsed until symptom alleviation and the frequency of subsequent medical interventions or hospital visits.

Findings from these trials describe patterns observed in the studies over very short follow-up durations. The evidence supporting use in acute exacerbations is largely derived from numerous acute-phase trials and established medical consensus. Research exploring the medicine's specific role in the long-term outcomes or prevention of future exacerbations following the completion of the short course remains less extensive. Also, evidence quality varies across studies when comparing prednisolone directly against other types of systemic corticosteroids used for acute care.


What Remains Uncertain About Преднизолон Research

For some indications, such as Complex Regional Pain Syndrome (CRPS), the evidence is considered limited, as studies relied on a modest number of small RCTs and systematic reviews have indicated low certainty for many findings. In these cases, research provides context but not individual predictions, and data show patterns related to symptom alleviation over short periods.

Overall, evidence highlights what is known—and what is still uncertain. Comparative evidence is lacking for many potential head-to-head comparisons against newer therapies. Findings describe group patterns; research does not provide individual predictions. Subgroup findings are uncertain in several contexts where specific populations were not adequately represented.

Key Studies & References

  1. Prednisolone Oral Solution/Tablet Official FDA Label and Drug Monograph

Frequently Asked Questions (FAQ)

Common questions about Преднизолон (FAQ)

Q: What is the difference between Prednisolone and other corticosteroids?

Official information describes Prednisolone (the active drug) as being distinct from Prednisone (a prodrug that requires activation by the liver). Prednisolone also has a specific potency when compared to other corticosteroids like Methylprednisolone or Dexamethasone. Standardized tables exist to help compare the strengths, which are used when transitioning between different steroid types.


Q: Can Prednisolone cause sleep problems?

Sleep disturbance, specifically insomnia, is a documented possible side effect of Prednisolone therapy. Product information commonly highlights that administration in the morning may help to align with the body’s natural cortisol rhythm and minimize this potential side effect.


Q: Can I drink coffee or alcohol while taking Prednisolone?

Regulatory literature generally advises against the consumption of alcohol while taking this medicine. Alcohol consumption is associated with known risks, and official prescribing information advises against combining alcohol with the drug, especially due to the potential for increased gastrointestinal irritation and general health risks.


Q: Are there studies confirming the effectiveness of Prednisolone for COVID-19?

Authoritative health organizations, such as the World Health Organization (WHO), have recommended corticosteroids (like Dexamethasone, which is equivalent to Prednisolone) for patients experiencing severe or critical illness due to COVID-19. These types of drugs are described as being useful for modulating the body's excessive immune reaction in acute, severe illness. They are generally not indicated for mild forms of the disease.


Q: What is Prednisolone 'pulse therapy'?

Pulse therapy refers to the medical practice of administering very high doses of glucocorticoids, often via an intravenous route, over a very short time period. This approach typically involves the use of high doses of corticosteroids for short periods, and is generally reserved for the management of acute, severe inflammatory conditions.


Q: Can Prednisolone cause swelling/edema?

Prednisolone has the potential to cause fluid retention in the body, which can sometimes lead to noticeable swelling (edema) or contribute to weight gain. This effect is related to the action of the medicine on sodium and water balance, and is generally influenced by the specific dose and duration of the medication.


Q: What blood tests are needed during Prednisolone treatment?

Prednisolone can potentially cause imbalances in blood parameters, such as elevated glucose or changes in electrolytes. Due to these potential effects, regulatory documentation advises that periodic monitoring of blood parameters, such as glucose and electrolyte levels, may be necessary during treatment.


Q: Is it true that it is harder to get pregnant after Prednisolone?

Official literature and small-scale studies have not indicated that the use of Prednisolone typically results in reduced fertility or makes it harder to conceive. However, its use during pregnancy is considered conditional and based on a risk-benefit assessment.


Q: Should I inform the dentist about taking Prednisolone?

Patients receiving long-term steroid treatment are often issued a special Steroid Treatment Card, as advised by regulatory bodies. The guidance for these cards emphasizes that the information should be available to a dentist prior to any surgical procedures or significant interventions.


Q: Can Prednisolone trigger acne?

Yes, official medical literature indicates that Prednisolone can trigger or worsen acne. This condition is sometimes referred to as steroid-induced acne. This side effect is typically observed with higher doses or extended treatment periods.


Q: How long does Prednisolone stay in the body after discontinuation?

The drug itself clears from the blood plasma within approximately 2 to 4 hours. However, the clinically relevant systemic effect—the suppression of the body's natural cortisol production (the HPA axis)—can persist for up to 12 months or longer after the treatment has ceased. This prolonged systemic effect highlights the need for a gradual reduction in dosage, as described in administration guidelines, rather than abrupt discontinuation.


Q: How can Prednisolone affect wound healing?

Prednisolone and other glucocorticoids are described in regulatory literature as agents that can potentially delay the healing process of wounds. This is considered one of the potential side effects related to its widespread systemic action on the immune and inflammatory response.


Q: Can I exercise while on Prednisolone treatment?

For competitive athletes, the oral or injectable use of Prednisolone is prohibited during competition periods, as it is classified as a glucocorticoid by international regulatory bodies. For individuals who are not competitive athletes, regulatory information notes that the risk of musculoskeletal side effects, such as osteoporosis, is a factor to consider when evaluating physical activity.


Q: What are the equivalent doses of Prednisolone and other steroids?

Standardized tables of equivalent doses exist to help compare the potency of Prednisolone with other systemic glucocorticoids, such as Dexamethasone or Methylprednisolone. These dose equivalencies are used to help healthcare providers facilitate switching between different steroids while aiming for a comparable therapeutic effect.


Q: Can Prednisolone affect libido?

Prolonged use of high doses of Prednisolone can potentially influence the body’s production of sex hormones. Official medical information indicates that this hormonal influence may, in some cases, be associated with a reduction in libido or other forms of sexual dysfunction.

How should Преднизолон be stored and disposed of?

Official Storage and Disposal Instructions

Prednisolone must be stored strictly according to regulatory requirements to maintain its stability and effectiveness.

Storage Requirement Details
Temperature Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F).
Environment Keep away from moisture, excess heat, and direct light. Do not freeze liquid forms.
Protection Keep the medication in its original, tightly closed container.
Child Safety Store Prednisolone well out of the reach and sight of children.
Stability Note Certain liquid solutions must be discarded 90 days after opening, regardless of the bottle's expiration date.

For disposal of unused or expired medicine, regulatory guidelines advise utilizing a drug take-back program. If a take-back option is unavailable, the medicine should be mixed with an undesirable substance (e.g., used coffee grounds, dirt) and placed in a sealed container before discarding in the household trash. Do not flush Prednisolone down the toilet or pour it down a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Преднизолон found in:

A-Z Index: